AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6973987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30903423 — intervention group
Group type: EXPERIMENTAL
Intervention: Group dynamic assessment
Number of subjects: 45
Study 30903423 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocabulary enhancement exercises
Number of subjects: 45
Study 30903423 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of group dynamic assessment and vocabulary exercises
Number of subjects: 45
Study 27484775 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month no-cost YMCA membership
Number of subjects: 91
Study 26104940 — intervention group
Group type: EXPERIMENTAL
Intervention: RTOG vascular expansion technique
Number of subjects: 7
Study 26104940 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified RTOG vascular expansion technique
Number of subjects: 7
Study 26104940 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVOTAL trial vascular expansion technique
Number of subjects: 7
Study 26104940 — intervention group
Group type: COMPARATOR
Intervention: RMH technique
Number of subjects: 7
Study 26104940 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified RTOG with 3-mm BEM
Number of subjects: 7
Study 23597289 — intervention group
Group type: EXPERIMENTAL
Intervention: SGI group (slow growth increase)
Number of subjects: 24
Study 21954478 — intervention group
Group type: EXPERIMENTAL
Intervention: Saw palmetto extract (320 mg/d)
Number of subjects: 369
Study 21954478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study 21954478 — intervention group
Group type: COMPARATOR
Intervention: Saw palmetto extract vs. placebo
Number of subjects: 369
Study 19703372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal sumatriptan 10 mg
Number of subjects: 12
Study 19703372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal sumatriptan 20 mg
Number of subjects: 12
Study 19703372 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous sumatriptan 6 mg
Number of subjects: 12
Study 16918641 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vitamin E
Number of subjects: 3
Study 16918641 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 3
Study 15530916 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholised red wine (DRW)
Number of subjects: 17
Study 15530916 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (RW)
Number of subjects: 17
Study 15530916 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 17
Study 10927040 — intervention group
Group type: COMPARATOR
Intervention: Multicolor fluorescence in situ hybridization (FISH) of peripheral blood lymphocytes and spermatozoa using a probe cocktail for chromosomes X, Y, and 21.
Number of subjects: 20
Study 9314462 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly intramuscular injections of benzathine penicillin G
Number of subjects: 115
Study 9314462 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 115
Study 8362174 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 6
Study 8362174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3741286 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0
Study 3741286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30557205 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual dementia experience (n = 56)
Number of subjects: 112
Study 30557205 — intervention group
Group type: COMPARATOR
Intervention: Standard teaching approaches
Number of subjects: 112
Study 29482218 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) intervention
Number of subjects: 314
Study 29482218 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 314
Study 29482218 — intervention group
Group type: EXPERIMENTAL
Intervention: CASA intervention
Number of subjects: 314
Study 27228979 — intervention group
Group type: EXPERIMENTAL
Intervention: Task sharing counselling intervention
Number of subjects: 26
Study 24177229 — intervention group
Group type: EXPERIMENTAL
Intervention: REORDER intervention
Number of subjects: 226
Study 24177229 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual
Number of subjects: 226
Study 22198517 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 168
Study 22198517 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 168
Study 20957693 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram with Interpersonal Psychotherapy (IPT)
Number of subjects: 124
Study 20957693 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram with Depression Care Management (DCM)
Number of subjects: 124
Study 17430381 — intervention group
Group type: EXPERIMENTAL
Intervention: BOTOX plus EPI 1:100,000
Number of subjects: 14
Study 17430381 — intervention group
Group type: COMPARATOR
Intervention: BOTOX
Number of subjects: 14
Study 16281190 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session modified behavioral treatment (SSBT)
Number of subjects: 59
Study 16281190 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition (WL)
Number of subjects: 59
Study 12061670 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous erythropoietin (600 U/kg per week) and oral iron (3 mg/kg per day)
Number of subjects: 27
Study 12061670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 12061670 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study 9706280 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin stroke prophylaxis
Number of subjects: 5
Study 7619034 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body immersion to the neck in water at 40 degrees C
Number of subjects: 0
Study 7619034 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion of two hands plus forearms in water at 42 degrees C
Number of subjects: 0
Study 7619034 — intervention group
Group type: COMPARATOR
Intervention: Passive rewarming
Number of subjects: 0
Study 7619034 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion of arms in hot water during immersion to the neck in cold water
Number of subjects: 0
Study 2696576 — intervention group
Group type: EXPERIMENTAL
Intervention: Capitation system of payment
Number of subjects: 0
Study 2696576 — intervention group
Group type: COMPARATOR
Intervention: Fee-for-service remuneration system
Number of subjects: 0
Study 339132 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg/day for 2 months
Number of subjects: 47
Study 339132 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks before and after indapamide
Number of subjects: 47
Study 31078463 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg orally twice daily and pembrolizumab 200 mg intravenously for 30 min on day 8 and every 3 weeks for cycles of 6 weeks for up to 2 years, followed by escalating doses of axitinib (2-10 mg) plus flat dose pembrolizumab.
Number of subjects: 33
Study 31078463 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 33
Study 28371702 — intervention group
Group type: EXPERIMENTAL
Intervention: High control over exposure (manipulated by joystick movement)
Number of subjects: 96
Study 28371702 — intervention group
Group type: COMPARATOR
Intervention: Low control over exposure (yoked with high control counterpart)
Number of subjects: 96
Study 25932592 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + CTG
Number of subjects: 24
Study 25932592 — intervention group
Group type: COMPARATOR
Intervention: CAF
Number of subjects: 24
Study 23937766 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold standard supervision strategies
Number of subjects: 390
Study 23937766 — intervention group
Group type: COMPARATOR
Intervention: Usual supervision practices
Number of subjects: 390
Study 21857330 — intervention group
Group type: EXPERIMENTAL
Intervention: Group physical activity intervention for 30 minutes three times a week for 16 weeks
Number of subjects: 77
Study 21857330 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 77
Study 18363201 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized formoterol fumarate (FFIS 20 microg)
Number of subjects: 351
Study 18363201 — intervention group
Group type: COMPARATOR
Intervention: DPI (Foradil Aerolizer; FA 12 microg)
Number of subjects: 351
Study 18363201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 15763453 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 4.5 microg
Number of subjects: 1130
Study 15763453 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 54 microg
Number of subjects: 1130
Study 15763453 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 0.5 mg
Number of subjects: 1130
Study 15763453 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 6 mg
Number of subjects: 1130
Study 11871761 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (n = 10)
Number of subjects: 19
Study 11871761 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 19
Study 10102971 — intervention group
Group type: EXPERIMENTAL
Intervention: Asacol (mesalazine) 1.2 g daily for 12 months in Group A (1-2 years remission)
Number of subjects: 112
Study 10102971 — intervention group
Group type: COMPARATOR
Intervention: Placebo in Group A (1-2 years remission)
Number of subjects: 112
Study 10102971 — intervention group
Group type: EXPERIMENTAL
Intervention: Asacol (mesalazine) 1.2 g daily for 12 months in Group B (over 2 years remission)
Number of subjects: 112
Study 10102971 — intervention group
Group type: COMPARATOR
Intervention: Placebo in Group B (over 2 years remission)
Number of subjects: 112
Study 8561490 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-by-side condition
Number of subjects: 40
Study 8561490 — intervention group
Group type: EXPERIMENTAL
Intervention: After-consumption condition
Number of subjects: 40
Study 8561490 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriateness ratings
Number of subjects: 40
Study 8561490 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum consumption
Number of subjects: 40
Study 8561490 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall consistency of hedonic responses
Number of subjects: 40
Study 2294526 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-facilitated exercise
Number of subjects: 22
Study 2294526 — intervention group
Group type: COMPARATOR
Intervention: Control (nonfeedback) Group
Number of subjects: 22
Study 429787 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine containing the recombinant of A/Victoria/3/75 with A/PR/8/34 virus
Number of subjects: 2115
Study 429787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2115
Study 31590097 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence plots (RP) features analysis from airflow (AF) recordings.
Number of subjects: 946
Study 31590097 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% oxygen desaturation index (ODI3).
Number of subjects: 946
Study 30308538 — intervention group
Group type: EXPERIMENTAL
Intervention: Short (24 hours) antibiotic administration
Number of subjects: 80
Study 30308538 — intervention group
Group type: COMPARATOR
Intervention: Extended (>24 hours) antibiotic administration
Number of subjects: 80
Study 28231619 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + CTG
Number of subjects: 42
Study 28231619 — intervention group
Group type: EXPERIMENTAL
Intervention: TUN + CTG
Number of subjects: 42
Study 28231619 — intervention group
Group type: COMPARATOR
Intervention: Both approaches
Number of subjects: 42
Study 25986294 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management support intervention delivered by registered nurses specialized in pain and palliative care.
Number of subjects: 0
Study 25986294 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 0
Study 25986294 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management support intervention.
Number of subjects: 0
Study 23225308 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac suppository-nabumetone combination therapy
Number of subjects: 0
Study 23225308 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone administration
Number of subjects: 0
Study 23225308 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 0
Study 23225308 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-MNA (active metabolite of nabumetone)
Number of subjects: 0
Study 21647699 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration (5 l/min) during spontaneous breathing in diabetic participants
Number of subjects: 136
Study 21647699 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration (5 l/min)
Number of subjects: 136
Study 21647699 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow breathing in normoxia
Number of subjects: 136
Study 19520194 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise program
Number of subjects: 56
Study 19520194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise program
Number of subjects: 56
Study 19520194 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 56
Study 19520194 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 16508743 — intervention group
Group type: EXPERIMENTAL
Intervention: Video laryngoscopy-guided application of cricoid pressure (group I)
Number of subjects: 170
Study 16508743 — intervention group
Group type: COMPARATOR
Intervention: Conventional, 'blind', application of cricoid pressure (group II)
Number of subjects: 170
Study 16508743 — intervention group
Group type: EXPERIMENTAL
Intervention: Video laryngoscopy (VIL)
Number of subjects: 170
Study 15987398 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-cushioned mattress
Number of subjects: 20
Study 15987398 — intervention group
Group type: COMPARATOR
Intervention: Conventional foam mattress
Number of subjects: 20
Study 15987398 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning (PP)
Number of subjects: 20
Study 15987398 — intervention group
Group type: EXPERIMENTAL
Intervention: Both support types
Number of subjects: 20
Study 12195197 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximally based gluteus maximus flap
Number of subjects: 12
Study 12195197 — intervention group
Group type: COMPARATOR
Intervention: Distally based gluteus maximus flap
Number of subjects: 12
Study 10207809 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum tumor markers CEA, CA 19-9, CA 50, CA 242
Number of subjects: 75
Study 8538183 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose 13-cis-retinoic acid (13cRA)
Number of subjects: 0
Study 8538183 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose followed by low-dose 13-cis-retinoic acid (13cRA)
Number of subjects: 0
Study 8538183 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant high-dose 13-cis-retinoic acid (13cRA)
Number of subjects: 0
Study 2142026 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 16949A 0.3 mg twice daily
Number of subjects: 24
Study 2142026 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 16949A 1.0 mg twice daily
Number of subjects: 24
Study 2142026 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 16949A 2.0 mg twice daily
Number of subjects: 24
Study 2142026 — intervention group
Group type: COMPARATOR
Intervention: CGS 16949A 0.1 mg twice daily
Number of subjects: 24
Study 2142026 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 16949A (all doses)
Number of subjects: 24
Study 482183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g daily
Number of subjects: 25
Study 482183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31904404 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training
Number of subjects: 42
Study 31904404 — intervention group
Group type: COMPARATOR
Intervention: Active control treatment
Number of subjects: 42
Study 30682704 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 65
Study 30682704 — intervention group
Group type: COMPARATOR
Intervention: low-fat diet
Number of subjects: 65
Study 27838569 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheo Knee II (microprocessor-controlled prosthetic knee)
Number of subjects: 9
Study 27838569 — intervention group
Group type: COMPARATOR
Intervention: NMPK (non-microprocessor-controlled prosthetic knee)
Number of subjects: 9
Study 26347894 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week group-based lifestyle intervention
Number of subjects: 50
Study 26347894 — intervention group
Group type: COMPARATOR
Intervention: Wait control
Number of subjects: 50
Study 23558857 — intervention group
Group type: EXPERIMENTAL
Intervention: Attribution retraining group therapy (ARGT)
Number of subjects: 129
Study 23558857 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 129
Study 21169287 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-CT
Number of subjects: 189
Study 21169287 — intervention group
Group type: COMPARATOR
Intervention: Conventional Work Up (CWU)
Number of subjects: 189
Study 21169287 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-CT (excluding patients where PET-CT was not performed)
Number of subjects: 189
Study 21169287 — intervention group
Group type: COMPARATOR
Intervention: Conventional Work Up (CWU) (excluding patients where PET-CT was not performed)
Number of subjects: 189
Study 19186960 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-enriched hydroxyapatite (MHA)
Number of subjects: 15
Study 19186960 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium sulfate (CS)
Number of subjects: 15
Study 19186960 — intervention group
Group type: COMPARATOR
Intervention: Control (unfilled sockets)
Number of subjects: 15
Study 17162400 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 42
Study 17162400 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 42
Study 17162400 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 42
Study 15389174 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy in addition to the stay-active concept
Number of subjects: 160
Study 15389174 — intervention group
Group type: COMPARATOR
Intervention: Stay-active concept only (reference group)
Number of subjects: 160
Study 11801963 — intervention group
Group type: EXPERIMENTAL
Intervention: p53+ status
Number of subjects: 105
Study 11801963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki-67+ status
Number of subjects: 105
Study 11801963 — intervention group
Group type: EXPERIMENTAL
Intervention: p53-/Ki-67- status
Number of subjects: 105
Study 9553435 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal ultraviolet blood irradiation (EUVBR)
Number of subjects: 67
Study 9553435 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal ultraviolet blood irradiation (EUVBR) with antibiotic therapy
Number of subjects: 67
Study 7851112 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protection sunscreen
Number of subjects: 1626
Study 7851112 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with beta-carotene (30 mg daily)
Number of subjects: 1626
Study 7851112 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protection sunscreen and dietary supplementation with beta-carotene
Number of subjects: 1626
Study 3187397 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 151
Study 3187397 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 151
Study 3187397 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 151
Study 29319350 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-length plate
Number of subjects: 16
Study 29319350 — intervention group
Group type: COMPARATOR
Intervention: Standard-length plate
Number of subjects: 16
Study 29862620 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian alignment (nocturnal bedtime)
Number of subjects: 14
Study 29862620 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian misalignment (12-hour inverted behavioural/environmental cycles)
Number of subjects: 14
Study 26994091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (400/100 mg) with tenofovir disoproxil/emtricitabine (245/200 mg) once daily
Number of subjects: 237
Study 26994091 — intervention group
Group type: COMPARATOR
Intervention: Maraviroc (300 mg) with tenofovir disoproxil/emtricitabine (245/200 mg) once daily
Number of subjects: 237
Study 26994091 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 237
Study 24656495 — intervention group
Group type: EXPERIMENTAL
Intervention: Calvarial bone dust (n=30, group I)
Number of subjects: 60
Study 24656495 — intervention group
Group type: COMPARATOR
Intervention: Calvarial bone and demineralized bone matrix (DBM; n=30, group II)
Number of subjects: 60
Study 22396769 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane-anthracycline-capecitabine regimen
Number of subjects: 0
Study 20388648 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma CgA levels at baseline
Number of subjects: 1233
Study 20388648 — intervention group
Group type: COMPARATOR
Intervention: Randomized treatments with n-3 polyunsaturated fatty acid or rosuvastatin
Number of subjects: 1233
Study 17684130 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokeless tobacco users
Number of subjects: 602
Study 15754239 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative therapy (IVO)
Number of subjects: 66
Study 15754239 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 66
Study 15754239 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative therapy followed by operative intervention
Number of subjects: 66
Study 11844964 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosurf (artificial surfactant)
Number of subjects: 22
Study 11844964 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 22
Study 10204832 — intervention group
Group type: COMPARATOR
Intervention: Medium or ultra-fine wheat bran with 10% energy as wheat gluten (1-month metabolic diet)
Number of subjects: 48